首页 > 市场调查报告书 > 製药

自体免疫疾病

类风湿性关节炎药物市场规模、份额和成长分析（按分子、销售管道、给药途径和地区划分）：产业预测（2026-2033 年）

市场调查报告书

商品编码

1898017

类风湿性关节炎药物市场规模、份额和成长分析（按分子、销售管道、给药途径和地区划分）：产业预测（2026-2033 年）

Rheumatoid Arthritis Drugs Market Size, Share, and Growth Analysis, By Molecule (Pharmaceuticals, Biopharmaceuticals), By Sales Channel (Prescription, Over-the-Counter (OTC)), By Route of Administration, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月24日 | 出版商:

SkyQuest | 英文 242 Pages | 商品交期: 3-5个工作天内

价格

简介目录

预计到 2024 年，全球类风湿性关节炎药物市场规模将达到 273.5 亿美元，到 2025 年将达到 289.9 亿美元，到 2033 年将达到 462.1 亿美元，预测期（2026-2033 年）的复合年增长率为 6%。

由于类风湿性关节炎发病率上升及其关节併发症数量不断增加，全球类风湿性关节炎治疗市场正经历显着增长。推动市场扩张的因素有很多，包括类风湿性关节炎盛行率的上升、对有效疗法的需求不断增长以及专利到期后生物相似药的兴起。此外，人口老化也增加了对传统DMARDs（缓解疾病抗风湿药）的依赖。政府旨在提高公众对类风湿性关节炎症状的认识并探索创新治疗方法的措施也进一步推动了市场发展。与主要产业参与者的合作促进了研发，而生物製药与DMARDs联合治疗的日益普及，则满足了需要个人化治疗方案的患者的治疗需求。

全球类风湿性关节炎药物市场成长要素

全球类风湿性关节炎的不断上升是推动全球类风湿性关节炎药物市场扩张的主要因素。人口老化以及生活方式和饮食习惯的变化，都加剧了疾病的发生率。这一趋势增加了对有效治疗类风湿性关节炎药物的需求，进一步推动了市场成长。随着人们对该疾病的认识不断提高，对创新治疗方法的需求也日益迫切，类风湿性关节炎药物市场持续发展，为治疗方案的改进和患者照护的提升提供了巨大的机会。

限制全球类风湿性关节炎药物市场的因素

长期使用某些类风湿性关节炎药物（尤其是生物製药和JAK抑制剂）的安全性问题，是限制市场成长的一大因素。潜在的不良反应，包括感染疾病风险、心血管问题和恶性肿瘤，往往会使患者和医疗服务提供者在采用这些治疗方法时持谨慎态度。因此，对副作用的担忧阻碍了这些治疗方法的推广和应用，最终减缓了其普及速度并限制了市场渗透率。这种犹豫不决影响了患者的整体治疗选择，并阻碍了类风湿性关节炎药物领域的发展。

全球类风湿性关节炎治疗市场趋势

全球类风湿性关节炎治疗市场的一个显着趋势是生物製药（包括单株抗体和JAK抑制剂）的应用日益广泛。这些先进疗法具有标靶作用机制，能够提高疗效并最大限度地减少副作用，尤其适用于中重度患者。随着医疗服务提供者和患者对这些创新疗法的益处认识不断提高，其应用率也显着上升。这项变化反映了整个产业向精准医疗的转变，使生物製药成为有效治疗类风湿性关节炎的首选方案。

艾伯维公司（美国）
辉瑞公司（美国）
安进公司（美国）
礼来公司（美国）
百时美施贵宝公司（美国）
强生公司（美国）
诺华公司（瑞士）
F. Hoffmann-La Roche Ltd（瑞士）
UCB SA（比利时）
武田药品工业株式会社（日本）
安斯泰来製药株式会社（日本）
卫材株式会社（日本）
中外製药株式会社（日本）
协和麒麟株式会社（日本）
太阳製药工业有限公司（印度）
鲁宾有限公司（印度）
Zydus Lifesciences Limited（印度）
印度西普拉有限公司
瑞迪博士实验室有限公司（印度）

结论与建议

简介目录

Product Code: SQSG35I2003

Global Rheumatoid Arthritis Drugs Market size was valued at USD 27.35 Billion in 2024 and is poised to grow from USD 28.99 Billion in 2025 to USD 46.21 Billion by 2033, growing at a CAGR of 6% during the forecast period (2026-2033).

The global rheumatoid arthritis drugs market is experiencing significant growth driven by rising arthritis incidences and joint complications. Several factors are contributing to this market expansion, including an increase in the prevalence of rheumatoid arthritis, heightened demand for effective treatments, and the release of patents leading to the rise of biosimilars. Additionally, a growing geriatric population is fostering an increased reliance on conventional DMARDs. Government initiatives aimed at enhancing awareness of rheumatoid arthritis symptoms and exploring innovative treatment options further boost the market. Collaborative efforts with key industry players facilitate research and development, while the popularity of combination therapies combining biologics and DMARDs is on the rise, catering to the therapeutic needs of patients requiring personalized treatment approaches.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Rheumatoid Arthritis Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Rheumatoid Arthritis Drugs Market Segments Analysis

Global Rheumatoid Arthritis Drugs Market is segmented by Molecule, Sales Channel, Route of Administration and region. Based on Molecule, the market is segmented into Pharmaceuticals andBiopharmaceuticals. Based on Sales Channel, the market is segmented into Prescription and Over-the-Counter (OTC). Based on Route of Administration, the market is segmented into Oral and Parenteral. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Rheumatoid Arthritis Drugs Market

The growing prevalence of rheumatoid arthritis worldwide is a key factor driving the expansion of the global rheumatoid arthritis drugs market. An aging population, coupled with lifestyle factors and dietary habits, has contributed to the increasing incidence of this condition. This trend has resulted in a heightened demand for effective treatments that can manage rheumatoid arthritis, further propelling market growth. As awareness of the disease increases and the need for innovative therapies becomes more pressing, the market for rheumatoid arthritis medications continues to evolve, indicating a significant opportunity for advancements in treatment options and patient care.

Restraints in the Global Rheumatoid Arthritis Drugs Market

Concerns regarding the safety of long-term usage of specific rheumatoid arthritis medications, particularly biologics and JAK inhibitors, significantly hinder the growth of the market. Both patients and healthcare providers often exercise caution in adopting these therapies due to potential adverse effects, including the risk of infections, cardiovascular issues, and malignancies. As a result, the apprehension surrounding the side effects stifles the willingness to embrace and integrate these treatments, ultimately slowing their adoption and limiting their market penetration. This hesitation impacts overall treatment options for patients and stalls progression within the rheumatoid arthritis drugs sector.

Market Trends of the Global Rheumatoid Arthritis Drugs Market

The global rheumatoid arthritis drugs market is witnessing a pronounced trend towards the growing adoption of biologic therapies, including monoclonal antibodies and JAK inhibitors. These advanced treatments offer targeted mechanisms of action that result in enhanced efficacy and minimized side effects, catering particularly to patients with moderate to severe forms of the disease. As healthcare providers and patients increasingly recognize the benefits of these innovative solutions, there has been a notable rise in their uptake. This shift reflects a broader movement within the industry towards precision medicine, positioning biologics as a preferred choice for effective rheumatoid arthritis management.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Landscape
Case Studies
Technological Analysis

Global Rheumatoid Arthritis Drugs Market Size by Molecule & CAGR (2026-2033)

Market Overview
Pharmaceuticals
- NSAIDs
- Analgesics
- DMARDs
- Glucocorticoids
Biopharmaceuticals
- Biologics
- TNF-a antagonists
- T-cell inhibitors
- CD20 antigen
- JAK inhibitors
- anti-IL6 biologics
- Biosimilars
- CD20 antigen
- TNF-a antagonists

Global Rheumatoid Arthritis Drugs Market Size by Sales Channel & CAGR (2026-2033)

Market Overview
Prescription
Over-the-Counter (OTC)

Global Rheumatoid Arthritis Drugs Market Size by Route of Administration & CAGR (2026-2033)

Market Overview
Oral
Parenteral

Global Rheumatoid Arthritis Drugs Market Size & CAGR (2026-2033)

North America (Molecule, Sales Channel, Route of Administration)
- US
- Canada
Europe (Molecule, Sales Channel, Route of Administration)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Molecule, Sales Channel, Route of Administration)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Molecule, Sales Channel, Route of Administration)
- Brazil
- Rest of Latin America
Middle East & Africa (Molecule, Sales Channel, Route of Administration)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

AbbVie Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
UCB S.A. (Belgium)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Astellas Pharma Inc. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eisai Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Chugai Pharmaceutical Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kyowa Kirin Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sun Pharmaceutical Industries Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lupin Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Zydus Lifesciences Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cipla Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dr. Reddy's Laboratories Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments